NervGen announced the appointment of Keith Vendola as CFO, effective immediately. Vendola will lead the company’s financial strategy and operations, including capital markets activity, financial planning, corporate development and supporting strategic initiatives. Vendola joins NervGen from Wugen where he served as CFO.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGEN:
- NervGen Pharma initiated with a Buy at H.C. Wainwright
- NervGen Pharma initiated with a Buy at Lucid Capital
- NervGen Pharma price target raised to $12 from $10 at Maxim
- NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
- NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting